Amgen Inc. (NASDAW: AMGN) reported positive Q2 results on June 30, 2015. Total revenue increased by 4% to $5.4 billion and EPS by 8% to 2.57.
The company generated $2.7 billion of free cash flow as compared to $2.1 billion for the same period in 2014.
Adjusted net income grew by aprox. 8% to $1.9 billion as compared to $1.8 billion for same Q2 last year.
Second Quarter 2015 GAAP EPS Increased 7 Percent to $2.15. 2015 Total Revenues and Adjusted EPS Guidance Increased to $21.1-$21.4 Billion and $9.55-$9.80, Respectively
| Year-over-Year | ||||||
| $Millions, except EPS and percentages | Q2 ’15 | Q2 ’14 | YOY Δ | |||
| Total Revenues | $ 5,370 | $ 5,180 | 4% | |||
| Adjusted Operating Income | $ 2,551 | $ 2,319 | 10% | |||
| Adjusted Net Income | $ 1,977 | $ 1,823 | 8% | |||
| Adjusted EPS | $ 2.57 | $ 2.37 | 8% | |||
| GAAP Operating Income | $ 2,076 | $ 1,902 | 9% | |||
| GAAP Net Income | $ 1,653 | $ 1,547 | 7% | |||
| GAAP EPS | $ 2.15 | $ 2.01 | 7% | |||
“Focused execution with our growth products drove record revenues in the second quarter, and expense discipline further leveraged earnings and our ability to invest in new and forthcoming launches,” said Robert A. Bradway, chairman and chief executive officer.
Amgen Inc. (Amgen) is a biotechnology company. The Company is engaged in discovering, developing, manufacturing and delivering human therapeutics.
sources: nasdaq, www.amgen.com